Eris Lifesciences Limited has secured shareholder approval to appoint Mr. Vineet Varma as an Independent Director. The resolution was passed via a remote e-voting process conducted under Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The appointment received overwhelming support, with 99.92% of the votes cast in favour of the motion.

The remote e-voting period commenced on April 24, 2026, and concluded on May 23, 2026. Mr. Ravi Kapoor, Practicing Company Secretary, served as the Scrutinizer for the process and submitted his report on May 25, 2026. The resolution required a special majority, which was achieved as the votes in favour significantly exceeded the votes against.

A total of 299 members participated in the remote e-voting process, representing 122,595,692 shares. The detailed voting breakdown reveals strong backing across different shareholder categories, including promoters and public institutions.

Voting Results Summary

The postal ballot notice was dispatched to shareholders on April 23, 2026. The company engaged MUFG Intime India Private Limited as the service provider to facilitate the electronic voting process. The results have been uploaded to the company’s website and the platform of the registrar and share transfer agent.

Eris Lifesciences has reported its audited consolidated financial results for the fourth quarter and fiscal year ended March 31, 2026, posting a sharp jump in net profit to 279.10 Crores compared to 102.35 Crores in the same period last year. Revenue from operations grew to 757 Crores from 705 Crores year-on-year, reflecting broad-based improvement across key financial metrics. For the full fiscal year, the company recorded a net profit of 647.51 Crores on revenue of 3,129.42 Crores.

Q4 Financial Highlights

The company's latest quarterly performance demonstrates a significant improvement in profitability and operational efficiency. The following table summarises the key consolidated financial metrics for the quarter:

EBITDA improved to 274 Crores from 252 Crores year-on-year, while EBITDA margin expanded to 36.20% from 35.80%, indicating improved cost efficiency alongside revenue growth.

Segment Performance

The Domestic Branded Formulations (DBF) segment reported a 12% year-on-year revenue growth to Rs. 671 Crores in Q4 FY26, with an EBITDA margin of 37%. The International Business segment recorded a revenue of Rs. 86 Crores for the quarter, impacted by supply chain disruptions, while full-year revenue grew 7% to Rs. 348 Crores.

Sundae Launch and Guidance

The company highlighted a robust start for its Gx Semaglutide brand, Sundae, achieving a 22% market share by prescription volume in April 2026. For FY27, the company provided guidance for DBF revenue growth at 1.3x of CVM growth and an EBITDA margin of 37%.

Dividend Declaration

The Board of Directors has declared an interim dividend of Rs. 7.21 per share (at the rate of 721%) on each fully paid-up equity share of Re. 1/- each for the financial year 2026-27. The record date for determining the eligibility of shareholders for the payment of the interim dividend has been fixed as Friday, May 29, 2026.